AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 16, 2024
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications
– Company to host conference call and webcast today, August 16th at 8:30 AM ET
Read more at globenewswire.com
